Front Row Advisors LLC Arbutus Biopharma Corp Transaction History
Front Row Advisors LLC
- $271 Million
- Q3 2024
A detailed history of Front Row Advisors LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Front Row Advisors LLC holds 10,500 shares of ABUS stock, worth $33,705. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,500
Previous 10,500
-0.0%
Holding current value
$33,705
Previous $32,000
25.0%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding ABUS
# of Institutions
155Shares Held
99.5MCall Options Held
2.31MPut Options Held
525K-
Morgan Stanley New York, NY21.7MShares$69.7 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$41.3 Million26.34% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$37.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$28.6 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.39MShares$26.9 Million10.86% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $481M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...